Clinical study with cefozopran in urinary tract infection and male genital infection

Keizo Suzuki, Masaki Horiba, Toshiyuki Tanaka, Yorio Naide, Kiyohito Ishikawa, Haruyoshi Asano, Norihiko Okijio

Research output: Contribution to journalArticlepeer-review


To evaluate the efficacy and safety of the novel injectable cephem cefozopran (CZOP), this drug was administered to 31 patients with infection in the field of urology. The subjects consisted of 28 patients with UTI (simple in 5 and complicated in 23) and 3 patients with bacterial prostatitis (acute in 2 and chronic in 1). The drug was administered by drip infusion in doses of 0.5 to 1.0 g once to three times daily for 3 to 15 days. According to the drug effect evaluation criteria for UTI, the response was classified as excellent in 3 of 13 patients with simple UTI and good or excellent in 16 of 19 patients with complicated UTI, the overall efficacy rate being 84.2 %. The drug benefited 2 of 3 patients with prostatitis. As for the safety of the drug, none of the patients treated had any side effects. As for the laboratory tests, a slight elevation in S-GPT was noted, and an elevation in eosinophils and the transient appearance of atypical lymphocytes were observed in 1 case each.

Original languageEnglish
Pages (from-to)616-621
Number of pages6
Publication statusPublished - 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Clinical study with cefozopran in urinary tract infection and male genital infection'. Together they form a unique fingerprint.

Cite this